<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Intensive Care Med</journal-id><journal-id journal-id-type="iso-abbrev">Intensive Care Med</journal-id><journal-title-group><journal-title>Intensive Care Medicine</journal-title></journal-title-group><issn pub-type="ppub">0342-4642</issn><issn pub-type="epub">1432-1238</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6096698</article-id><article-id pub-id-type="pmid">30062576</article-id><article-id pub-id-type="publisher-id">5308</article-id><article-id pub-id-type="doi">10.1007/s00134-018-5308-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original</subject></subj-group></article-categories><title-group><article-title>Intensive care support and clinical outcomes of patients with Ebola virus disease (EVD) in West Africa</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8496-1620</contrib-id><name><surname>Langer</surname><given-names>Martin</given-names></name><address><phone>+393395470727</phone><email>martin.langer@emergency.it</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Portella</surname><given-names>Gina</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Finazzi</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Chatenoud</surname><given-names>Liliane</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lanini</surname><given-names>Simone</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Vairo</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Fowler</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Miccio</surname><given-names>Rossella</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ippolito</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Bertolini</surname><given-names>Guido</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Strada</surname><given-names>Gino</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1757 2822</institution-id><institution-id institution-id-type="GRID">grid.4708.b</institution-id><institution>Dipartimento di Oncologia e Onco-Ematologia, </institution><institution>University of Milan, </institution></institution-wrap>Milan, Italy </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0807 2568</institution-id><institution-id institution-id-type="GRID">grid.417893.0</institution-id><institution>IRCCS Istituto Nazionale dei Tumori, </institution></institution-wrap>Milan, Italy </aff><aff id="Aff3"><label>3</label>EMERGENCY-NGO, Via Santa Croce 19, 20122 Milan, Italy </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000000106678902</institution-id><institution-id institution-id-type="GRID">grid.4527.4</institution-id><institution>Dipartimento di Epidemiologia Clinica, </institution><institution>IRCCS Istituto di Ricerche Farmacologiche &#x0201c;Mario Negri&#x0201d;, </institution></institution-wrap>Ranica, BG Italy </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.414603.4</institution-id><institution>IRCCS Istituto Nazionale Malattie Infettive &#x0201c;Lazzaro Spallanzani&#x0201d;, </institution></institution-wrap>Rome, Italy </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.416745.5</institution-id><institution>Departments of Medicine and Critical Care Medicine, </institution><institution>Sunnybrook Hospital, </institution></institution-wrap>Toronto, ON Canada </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>7</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>7</month><year>2018</year></pub-date><pub-date pub-type="ppub"><year>2018</year></pub-date><volume>44</volume><issue>8</issue><fpage>1266</fpage><lpage>1275</lpage><history><date date-type="received"><day>12</day><month>6</month><year>2018</year></date><date date-type="accepted"><day>6</day><month>7</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">We investigate the impact on outcome of different levels of supportive treatment in Ebola virus disease (EVD). The NGO EMERGENCY delivered care sequentially at two Ebola Treatment Centres (ETC) in Sierra Leone: first at Lakka (fluids, symptomatic, antibiotic, antimalaria treatment, and hospital level medical care), and thereafter in Goderich, adding organ support in the only African ETC with an equipped and staffed intensive care unit (ETC-ICU).</p></sec><sec><title>Methods</title><p id="Par2">The primary outcome in this retrospective cohort study was in-ETC mortality. Secondarily, we used multivariable logistic regression to investigate the independent impact of the IC on mortality by comparing patients in two ETCs, adjusting for potential confounders, including the viral load (base-10 logarithm in copies/ml) (LVL), modelled as a piecewise linear function. Mortality was plotted versus LVL. Confidence bands were constructed by a bootstrap technique. The number of hospital-free days within 28 was computed to assess the burden of EVD.</p></sec><sec><title>Results</title><p id="Par3">Data from 229 EVD patients were analysed (123 in Lakka, 106 in Goderich). Crude analysis showed a non-statistically significant difference in mortality (57.7% in Lakka vs 50.0% in Goderich; <italic>p</italic>&#x02009;=&#x02009;0.19). Age and LVL were associated with mortality. Adjusted mortality was lower at the Goderich ICU-ETC (<italic>p</italic>&#x02009;=&#x02009;0.055). This difference was observed with 80% confidence for patients with LVL between 7.5 and 8.5&#x000a0;copies/ml. Hospital-free days (of 28&#x000a0;days) were greater (7.7 vs 5.5; <italic>p</italic>&#x02009;=&#x02009;0.03) for patients treated in the ICU-ETC.</p></sec><sec><title>Conclusions</title><p id="Par4">Provision of critical care to patients with EVD is feasible in resource-limited settings and was associated with improved survival and less time in hospital.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1007/s00134-018-5308-4) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Ebola virus disease</kwd><kwd>Intensive care</kwd><kwd>Multiple organ failure</kwd><kwd>Health-care in resource limited countries</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002803</institution-id><institution>Fondazione Cariplo</institution></institution-wrap></funding-source><award-id>grant [2014-1962]</award-id><principal-award-recipient><name><surname>Finazzi</surname><given-names>Stefano</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature and ESICM 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="FPar6"><title>Take-home message:</title><p id="Par222">
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="2">An Intensive Care Unit (ICU) as part of an Ebola Treatment Centre (ETC) was run by the NGO EMERGENCY and the Istituto Malattie Infettive &#x0201c;Spallanzani&#x0201d; in Goderich, Sierra Leone during the last 5 months in the 2013-16 outbreak. Building and running an ICU with western standard in an ETC was possible also in this very difficult setting. This allowed also some research activity, essential to evaluate the interventions directly on the field in real life conditions during an epidemic and with the pressure of large numbers of cases.<break/>The outcome of the 106 patients treated in the ICU-ETC was compared in a before-after study to the outcome of the previous cohort of 123 patients treated by the same NGO in Lakka without an ICU facility. Patient risk factors, mainly the viral load at admission were adjusted as potential confounders. The availability of the ICU in the ETC led to a lower mortality in Goderich (p=0.055). This difference was observed with 80% confidence for patients with an intermediate range of viral load, indicating an intermediate probability of death (50-70%). Relatively small numbers in each subgroup and other possible risk factors limit this analysis.<break/>The already high level of care in Lakka, the first ETC, corresponding essentially to the recently published guidelines, can be improved with the availability of an Intensive Care Unit. However also the maximal supportive effort without effective antivirals seems not able to lower mortality to an acceptable level. Intensive care and effective antiviral seem both necessary in the fight against Ebola.</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec1"><title>Introduction</title><p id="Par5">The Ebola virus disease (EVD) outbreak in West Africa in 2013&#x02013;2016 was the largest, longest-lasting epidemic of its kind, and for the first time also involved non-African countries. The outbreak led to a broader understanding of Ebola epidemiology and heightened recognition of the need to respond rapidly to interrupt transmission early [<xref ref-type="bibr" rid="CR1">1</xref>]. Considerable progress has also been made on vaccine development [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>], but there is still limited knowledge on EVD pathophysiology [<xref ref-type="bibr" rid="CR7">7</xref>] and therapeutic yielded inconclusive findings [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par6">Management guidelines [<xref ref-type="bibr" rid="CR14">14</xref>] developed from previous outbreaks and available in 2013, focused on patient cohorting and healthcare worker safety, proposing treatments that could be delivered in resource-limited settings in rural areas with limited access to medical care.</p><p id="Par7">In 2014, many groups operating in the field [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>] endorsed the need for more aggressive symptomatic treatment, treatment of dehydration and related electrolyte imbalances and organ-supporting care. Human resources and funding, combined with experience from EVD treatment of patients transported to North America and Europe, strengthened the idea of critical care provision in resource-constrained settings.</p><p id="Par8">EMERGENCY, an Italian NGO (<ext-link ext-link-type="uri" xlink:href="http://www.emergency.it">http://www.emergency.it</ext-link>), was founded in 1994 with the primary mission of delivering care to civilian war victims worldwide. Since 2001 it has also been running a Surgical and Paediatric Centre on the outskirts of Freetown, Sierra Leone. At the start of the epidemic, the Ministry of Health of Sierra Leone invited EMERGENCY to contribute to the fight against Ebola. The NGO rapidly built a patient assessment centre in Lakka to provide clinical triage, assessment and Ebola diagnostic testing, which soon became a patient Ebola Treatment Centre (ETC). A second ETC, in Goderich Sierra Leone was subsequently constructed, incorporating a well-equipped intensive care unit (ICU), capable of providing 24&#x000a0;h nursing and medical assessment/support, mechanical ventilation, intravenous vasoactive medications, and renal replacement therapy (Supplementary information, S2). To our knowledge, this was the first ever, dedicated ICU-ETC in Africa.</p><p id="Par9">Our aims for this retrospective cohort study was to describe the feasibility of providing intensive care with organ-supporting treatment to patients with Ebola in a resource-limited setting, to describe patient outcomes, and to compare outcomes of patients between two distinct treatment settings (Goderich ETC with an ICU vs Lakka ETC with no ICU), adjusting for predictors of survival, including patient age and viral load at admission [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>].</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and setting</title><p id="Par10">This retrospective cohort study includes all consecutive patients affected by EVD hospitalized in two ETCs in Sierra Leone, from 19/09/2014 to 12/12/2014 in the Lakka Holding and Treatment Centre and from 12/12/2014 to 28/05/2015 in the Goderich ETC-ICU. Both ETCs were located near Freetown, Sierra Leone. More detailed information on the staff, facility, and operational procedures are provided in the Supplementary Material, S1 and S2. The main characteristics and differences are reported in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Main patient management characteristics of EMERGENCY NGO&#x02019;s two Ebola Treatment Centres (ETC) in Freetown, Sierra Leone; September 2014&#x02013;May 2015</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">ETC Lakka (September 19&#x02013;December 13, 2014)</th><th align="left">ETC-ICU Goderich (December 14, 2014&#x02013;May 28, 2015)</th></tr></thead><tbody><tr><td align="left">Structure</td><td align="left">Tents</td><td align="left">Brick walls (ICU)&#x02009;+&#x02009;tents</td></tr><tr><td align="left">Number of beds</td><td align="left">5 holding/17 treatment</td><td align="left">22 holding/24 ICU/50 ward</td></tr><tr><td align="left">Running water and electricity</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">Air conditioning</td><td align="left">Yes (inadequate)</td><td align="left">Yes</td></tr><tr><td align="left">Oxygen</td><td align="left">Yes (concentrators max 5&#x000a0;l/person)</td><td align="left">Yes (concentrators max 10&#x000a0;l/person)</td></tr><tr><td align="left">Virology laboratory</td><td align="left">External</td><td align="left">Internal</td></tr><tr><td align="left">Laboratory at point-of-care</td><td align="left">Partial/last weeks</td><td align="left">Yes</td></tr><tr><td align="left">Radiology</td><td align="left">No</td><td align="left">Yes (from March 15/2015)</td></tr><tr><td align="left">Standard monitoring (EKG, HR pulse oximetry, non-invasive blood pressure)</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">Urinary catheter and fluid balance</td><td align="left">partially</td><td align="left">Yes</td></tr><tr><td align="left">Artificial nutrition</td><td align="left">Parenteral</td><td align="left">Parenteral/enteral</td></tr><tr><td align="left">IV fluid replacement, where necessary</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">Blood and blood products</td><td align="left">Only whole O Rh neg blood</td><td align="left">Yes</td></tr><tr><td align="left">Inotropes/vasoactive medication</td><td align="left">Dopamine</td><td align="left">Noradrenaline, Adrenaline, Dopamine</td></tr><tr><td align="left">Central venous lines</td><td align="left">Yes, last month</td><td align="left">Yes</td></tr><tr><td align="left">Arterial line and pressure monitoring</td><td align="left">No</td><td align="left">Yes</td></tr><tr><td align="left">Advanced cardiovascular monitoring (PICCO)</td><td align="left">No</td><td align="left">Yes</td></tr><tr><td align="left">Blood gas analyser</td><td align="left">No</td><td align="left">Yes</td></tr><tr><td align="left">Tracheal intubation and mechanical ventilation</td><td align="left">No</td><td align="left">Yes</td></tr><tr><td align="left">Continuous renal replacement therapy</td><td align="left">No</td><td align="left">Yes</td></tr><tr><td align="left">Individual time limit for working inside red zone</td><td align="left">60&#x02032;</td><td align="left">120&#x02032;</td></tr><tr><td align="left">No. doctors, mean</td><td align="left">5 MDs</td><td align="left">14 MDs</td></tr><tr><td align="left">No. international nurses, mean</td><td align="left">6</td><td align="left">20</td></tr><tr><td align="left">No. intensivisits, total</td><td align="left">2 intensivists</td><td align="left">5 intensivists</td></tr><tr><td align="left">Time in h/24&#x000a0;h any MD present in red zone</td><td align="left">5</td><td align="left">15</td></tr></tbody></table><table-wrap-foot><p>The staff calculation was performed by calculating the mean number of staff members per month</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec4"><title>Laboratory</title><p id="Par11">The plasma concentration of Ebola virus (EBOV) RNA (viral load) was measured using a real-time reverse transcriptase PCR (RT-PCR) assay (RealStar Filovirus Screen. RT-PCR 1.0 kit, Altona Diagnostics), with a limit of detection of 10<sup>3</sup>&#x000a0;cp/ml of EBOV RNA. Viral RNA quantification was based on a standard reference curve provided by the kit manufacturer, spanning up to 10<sup>9</sup>&#x000a0;cp/ml of EBOV RNA. For the sake of simplicity, further analyses were performed using the base 10 logarithm of the viral load (LVL) measured in cp/ml.</p><p id="Par12">At the start of the epidemic, before implementing its own virology laboratory, EMERGENCY collaborated with the WHO South Africa Ebola laboratory, which used the same diagnostic test.</p></sec><sec id="Sec5"><title>Admitted patients</title><p id="Par13">Patients reaching the facility with suspected EVD were admitted, under observation, to the Holding and Treatment Centre, and their symptoms treated while awaiting the RT-PCR test results. Only patients with laboratory-confirmed EVD from the holding centre, or those with EVD transferred from other facilities, were admitted for treatment.</p></sec><sec id="Sec6"><title>Risk factors at admission</title><p id="Par14">Demographic information including age, gender, symptoms, and possible time of Ebola exposure were collected on standardised clinical case report forms. LVL was recorded from the first diagnostic blood sample at admission. Other risk factors at admission, including markers of organ damage (renal, liver, coagulation etc.), were not systematically collected in the early months and cannot therefore be included in the analysis.</p></sec><sec id="Sec7"><title>Definition of outcome</title><p id="Par15">A survivor is defined as a patient discharged alive. Discharge of patients from the ETCs occurred after two negative RT-PCR blood tests performed at least 24&#x000a0;h apart.</p></sec><sec id="Sec8"><title>Co-interventions: investigational antiviral treatments</title><p id="Par16">Fluids and electrolytes were administered by mouth or intravenously according symptoms, diuresis and fluid balance; all patients were treated for symptoms as nausea, anxiety, and pain. Antibiotics were administered from admission and antimalaria treatment was discontinued only if negative tests became available.</p><p id="Par17">Only a few doses of compassionate use investigational antiviral treatments were available. Two patients received ZMAb and towards the end of the outbreak, Goderich ETC took part in the Prevail II trial [<xref ref-type="bibr" rid="CR8">8</xref>], randomizing five patients to standard care plus ZMapp (two patients) versus standard care alone (three patients). Based on the available preclinical literature suggesting in vitro and in vivo efficacy [<xref ref-type="bibr" rid="CR24">24</xref>], a randomised clinical trial protocol was developed to investigate the efficacy of treatment of EVD with amiodarone. The trial was registered at ClinicalTrials.gov (NCT02307591) (see Supplementary material S4 for details).</p><p id="Par18">While awaiting clinical trial initiation, and after approval by two Italian Ethics Committees, given the pre-existing high mortality rate and lack of known effective therapies, amiodarone was administered on a compassionate basis to 100 patients. Compassionate use was stopped between December 2014 and February 2015 by request of the Sierra Leonean Government, pending the opinion of the specific Ethics Committee (definitive approval granted April 23, 2015). Further information on the treatment with amiodarone is reported in the Supplementary material S4.</p></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par19">Descriptive analyses were presented as frequencies, proportions, means and standard deviations, medians and interquartile ranges (IQR), where appropriate to characterize patients and their clinical outcomes. Proportions were compared using the <italic>&#x003c7;</italic><sup>2</sup> test or Fisher Test, whereas comparisons between continuous variables were expressed through the <italic>t</italic> test or Wilcoxon rank-sum test, as appropriate. The number of hospital-free days within 28&#x000a0;days was calculated to compare the burden of EVD in terms of hospitalization in the two ETCs, avoiding bias due to mortality rate differences [<xref ref-type="bibr" rid="CR25">25</xref>]. During the 28-day follow-up period most, but not all, EVD patients either died or recovered. The number of hospital-free days for a patient with <italic>x</italic> days of hospitalisation was 28&#x02009;&#x02212;&#x02009;<italic>x,</italic> if the patient recovered within 28&#x000a0;days, and 0 if the patient recovered after 28&#x000a0;days or died. Hence, the higher the value of this indicator the lower the burden of hospitalization (as the patient recovered earlier), while deceased patients were considered equivalent to alive patients with a long recovery time.</p><p id="Par20">Multivariable logistic regression models were used to determine independent factors associated with EVD patient mortality. ETC was forced in the model to explore the secondary endpoint of association of intensive care availability on mortality. To test any relationship between the logit and the LVL, the former was modelled as a continuous piecewise linear function of the latter. The Akaike Information Criterion (AIC) [<xref ref-type="bibr" rid="CR26">26</xref>] was minimised with respect to the cut-off values of LVL where the slope of the piecewise linear function changed. Interactions between ETC and the other variables were only included when they significantly reduced the AIC. The interaction between ETC and the above-described transformation of the viral load was also tested in this step. This allowed different piecewise linear transformations (parametrised by the number and values of the cut-offs) of the LVL for the two ETCs. Missing records were excluded from the analysis.</p><p id="Par21">The odds ratio (OR) of the two ETCs, i.e., the exponential of the difference <italic>d</italic> between the logit of the two ETCs (<italic>d</italic>&#x02009;=&#x02009;logit<sub>Lakka</sub>&#x02009;&#x02013;&#x02009;logit<sub>Goderich</sub>), was plotted as a function of viral load, with the bootstrap-based confidence band. Hence, mortality in Lakka was higher than in Goderich when OR was larger than one. The OR was statistically significant for those viral load values for which the confidence band was above the line OR&#x02009;=&#x02009;1. To identify the range of clinically relevant phenomena, two confidence bands were constructed at the 95 and 80% levels, respectively.</p><p id="Par22">The adjusted probability of death was then plotted for each ETC with the respective confidence bands to determine how mortality varied as a function of viral load in the two ETCs. All variables except LVL and ETC were chosen to be equal to their mean values. The width of the confidence bands for Lakka and Goderich was estimated by Payton et al. [<xref ref-type="bibr" rid="CR27">27</xref>] approximate method. This procedure is designed to evaluate, with a given significance level, whether two confidence intervals overlap (Supporting information, S5).</p><p id="Par23">The role played by viral load at admission as a predictor of mortality within 20&#x000a0;days of hospitalisation, was also described using Kaplan&#x02013;Meier curves in strata of LVL, overall and for each ETC (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The cut-offs separating the strata were determined as the LVL values at which mortality in one ETC becomes higher or lower than in the other ETC at the 80% confidence level (as described in the previous paragraph). Graphically, these values correspond to the points where the 80% confidence band of the logit difference <italic>d</italic> crosses the horizontal axis <italic>d&#x02009;</italic>=0. Differences between Kaplan&#x02013;Meier curves in these strata were assessed by the log-rank test.</p><p id="Par24"><italic>p</italic> values lower than 0.05 were considered significant in two-tailed tests. All analyses were performed using R software, version 3.3.3, and SAS software, version 9.4.</p><p id="Par25">More details on the statistical elaboration are reported in Supplementary materials, S5.</p></sec><sec id="Sec10"><title>Funding</title><p id="Par26">Goderich ETC was built during the outbreak, in the framework of a project to build seven Ebola treatment centres funded by DFID (Department for International Development&#x02014;GOV.UK). In accordance with treatment criteria and based on the previous 3&#x000a0;months&#x02019; experience, the Centre was co-designed by EMERGENCY&#x02019;s technical/engineering staff. Fitting it out for intensive care delivery resulted in additional costs, borne by the NGO, in the amount of approximately &#x020ac;450,000. The Istituto di Malattie Infettive &#x0201c;Lazzaro Spallanzani&#x0201d;, which ran the virological laboratory, was supported by a &#x0201c;Ricerca Corrente IRCCS&#x0201d; grant; Ministry of Foreign Affairs, Italy (See Supplementary material S2 for more details). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Patients and settings</title><p id="Par27">Data were analysed on 229 patients with a laboratory-confirmed diagnosis of EVD, admitted to the two ETCs (123 at the ETC in Lakka, 106 at the ETC-ICU in Goderich). All patients with confirmed EVD received supportive treatment and were followed up to the endpoint (recovery or death). The study flow chart is shown in the supplementary material (Fig S3.1).</p><p id="Par28">The patients admitted to the ETCs did not differ in terms of gender, while patients admitted to Goderich-ETC were older (mean age 29.7) than those admitted to Lakka-ETC (mean age 27.8&#x000a0;years) (<italic>p&#x02009;</italic>=&#x02009;0.02).</p><p id="Par29">No major differences emerged between ETCs for admission viral load, or time from symptom onset to ETC-admission (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Demographic and clinical characteristics of 227 Ebola virus disease (EVD) patients at admission to two Ebola treatment centres (ETC)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Total (<italic>N</italic>&#x02009;=&#x02009;229)<break/><italic>N</italic> (%)</th><th align="left">Lakka-ETC (<italic>N</italic>&#x02009;=&#x02009;123)<break/><italic>N</italic> (%)</th><th align="left">Goderich-ETC (<italic>N</italic>&#x02009;=&#x02009;106)<break/><italic>N</italic> (%)</th><th align="left"><italic>p</italic> value<sup>a</sup></th></tr></thead><tbody><tr><td align="left" colspan="5">Sex</td></tr><tr><td align="left">&#x000a0;Women</td><td align="left">114 (49.8)</td><td align="left">60 (48.8)</td><td align="left">54 (51.0)</td><td align="left">0.74</td></tr><tr><td align="left">Age, years (mean/median/(IQR)</td><td align="left">29.7, 27.0/(20.0&#x02013;38.0)</td><td align="left">27.8, 26.0/(20.0&#x02013;36.0)</td><td align="left">31.8, 29.0/(20.0&#x02013;42.0)</td><td align="left">0.02</td></tr><tr><td align="left">&#x000a0;0&#x02013;10</td><td align="left">22 (9.6)</td><td align="left">15 (12.2)</td><td align="left">7 (6.7)</td><td align="left"/></tr><tr><td align="left">&#x000a0;11&#x02013;18</td><td align="left">28 (12.2)</td><td align="left">12 (9.8)</td><td align="left">16 (15.4)</td><td align="left"/></tr><tr><td align="left">&#x000a0;19&#x02013;45</td><td align="left">145 (63.3)</td><td align="left">85 (69.1)</td><td align="left">60 (57.7)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02265;&#x02009;46</td><td align="left">32 (14.0)</td><td align="left">11 (8.9)</td><td align="left">21 (20.2)</td><td align="left"/></tr><tr><td align="left">&#x000a0;<italic>Missing</italic></td><td align="left">2 (0.9)</td><td align="left">&#x02013;</td><td align="left">2 (1.9)</td><td align="left"/></tr><tr><td align="left" colspan="5">LVL (copies/ml) at admission</td></tr><tr><td align="left">&#x000a0;&#x0003c;&#x02009;7.5</td><td align="left">84 (36.7)</td><td align="left">49 (39.8)</td><td align="left">35 (33.0)</td><td align="left"/></tr><tr><td align="left">&#x000a0;7.5&#x02013;8.4</td><td align="left">78 (34.1)</td><td align="left">42 (34.1)</td><td align="left">36 (34.0)</td><td align="left">0.29</td></tr><tr><td align="left">&#x000a0;&#x02265;&#x02009;8.5</td><td align="left">47 (20.5)</td><td align="left">21 (17.1)</td><td align="left">26 (24.5)</td><td align="left"/></tr><tr><td align="left">&#x000a0;<italic>Missing</italic></td><td align="left">
<italic>20 (8.7)</italic>
</td><td align="left">
<italic>11 (8.9)</italic>
</td><td align="left">
<italic>9 (8.5)</italic>
</td><td align="left"/></tr><tr><td align="left">&#x000a0;Mean/median/(IQR)</td><td align="left">7.6/7.8/(6.9&#x02013;8.5)</td><td align="left">7.6/7.8/(6.8&#x02013;8.4)</td><td align="left">7.7/7.9/(7.1&#x02013;8.6)</td><td align="left"/></tr><tr><td align="left">Time between symptom onset and hospital admission (day), mean/median/(IQR)</td><td align="left">4.9/4.0/(3.0&#x02013;6.0)</td><td align="left">5.0/4.0/(3.0&#x02013;6.0)</td><td align="left">4.8/5.0/(3.0&#x02013;6.0)</td><td align="left">0.95</td></tr><tr><td align="left">&#x000a0;0&#x02013;2</td><td align="left">43 (18.8)</td><td align="left">24 (19.5)</td><td align="left">19 (17.9)</td><td align="left"/></tr><tr><td align="left">&#x000a0;3&#x02013;5</td><td align="left">101 (44.1)</td><td align="left">55 (44.7)</td><td align="left">46 (43.4)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x0003e;&#x02009;5</td><td align="left">76 (33.2)</td><td align="left">44 (35.8)</td><td align="left">32 (30.2)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Missing</td><td align="left">9 (3.9)</td><td align="left">&#x02013;</td><td align="left">9 (8.5)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p><italic>LVL</italic> base-10 logarithm of&#x000a0;viral load, measured in copies per ml</p><p><italic>IQR</italic> Interquartile range</p><p><sup>a</sup><italic>&#x003c7;</italic><sup>2</sup> test or Fisher&#x02019;s exact test or Wilcoxon&#x02019;s Rank-Sum Test for continuous variables</p></table-wrap-foot></table-wrap>
</p><p id="Par30">The clinical manifestations and contact history of the 229 EVD patients are shown in the Supplementary material S3. None of the 13 clinical symptoms reported during the admission visit were significantly associated with mortality. The provision of interventions associated with intensive care were more common at the Goderich ETC-ICU: central venous catheter in 62 versus 12 patients (58.5 vs 9.8%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), mechanical ventilation for any duration in 33 (14.4%) and renal replacement therapy in 21 (9.2%) versus no patients in the ETC Lakka. Twenty patients had both ventilation and renal replacement therapy. Dopamine infusion was the only vasoactive medication possible in Lakka (12 patients; 1 survivor); Noradrenaline and/or Adrenaline (26 patients; 3 survivors), administered via syringe-pump and invasive monitoring of arterial pressure, central venous pressure and advanced hemodynamic assessment (Picco) in selected patients, were available in Goderich.</p></sec><sec id="Sec13"><title>Clinical outcomes</title><p id="Par31">The mean number of hospital-free days (of 28) days of admission was significantly higher in the Goderich ETC-ICU (7.7 vs 5.5&#x000a0;days; <italic>p&#x02009;</italic>=&#x02009;0.03, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Hospital stay and hospital-free days in two Ebola Treatment Centres (ETC)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Total (<italic>N</italic>&#x02009;=&#x02009;229)<break/><italic>N</italic> (%)</th><th align="left">Lakka-ETC (<italic>N</italic>&#x02009;=&#x02009;123)<break/><italic>N</italic> (%)</th><th align="left">Goderich-ETC (<italic>N</italic>&#x02009;=&#x02009;106)<break/><italic>N</italic> (%)</th><th align="left"><italic>p</italic> value<sup>a</sup></th></tr></thead><tbody><tr><td align="left">Hospital stay (days), mean, medan/(IQR)</td><td align="left">9.2, 8.0/(4.0&#x02013;14.0)</td><td align="left">9.3, 8.0/(4.0&#x02013;14.0)</td><td align="left">9.0, 8.0/(4.0&#x02013;13.0)</td><td align="left">0.66</td></tr><tr><td align="left">&#x000a0;0&#x02013;4</td><td align="left">73 (32.2)</td><td align="left">39 (31.7)</td><td align="left">34 (32.7)</td><td align="left"/></tr><tr><td align="left">&#x000a0;5&#x02013;10</td><td align="left">60 (26.4)</td><td align="left">30 (24.4)</td><td align="left">30 (28.8)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02265;&#x02009;11</td><td align="left">94 (41.4)</td><td align="left">54 (43.9)</td><td align="left">40 (38.5)</td><td align="left"/></tr><tr><td align="left">Hospital-free days within 28&#x000a0;days of hospitalisation, mean/median/(IQR)</td><td align="left">6.5, 0.0 (0.0&#x02013;14.0)</td><td align="left">5.5, 0.0 (0.0&#x02013;13.0)</td><td align="left">7.7, 2.5 (0.0&#x02013;15.0)</td><td align="left">0.03</td></tr><tr><td align="left">&#x000a0;0<sup>b</sup></td><td align="left">126 (55.0)</td><td align="left">73 (59.3)</td><td align="left">53 (50.0)</td><td align="left"/></tr><tr><td align="left">&#x000a0;1&#x02013;14</td><td align="left">52 (22.7)</td><td align="left">31 (25.2)</td><td align="left">21 (19.8)</td><td align="left"/></tr><tr><td align="left">&#x000a0;15&#x02013;28</td><td align="left">50 (21.8)</td><td align="left">19 (15.5)</td><td align="left">31 (29.2)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p><italic>IQR</italic> Interquartile range</p><p><sup>a</sup><italic>&#x003c7;</italic><sup>2</sup> test or Fisher exact test</p><p><sup>b</sup>This category includes 71 and 53 patients who died in Lakka and Goderich, respectively, plus two survivors from Lakka and one from Goderich, discharged after 28&#x000a0;days</p></table-wrap-foot></table-wrap>
</p><p id="Par32">The overall crude case fatality rate (CFR) was 54.1% (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). No statistical differences were observed between patients who survived and who died of EVD in terms of gender, age and time from symptom onset to hospital admission. CFR differed substantially according viral load at admission, ranging from approximately 30% for patients with LVL&#x02009;&#x0003c;&#x02009;7.5 (low) to over 80% for patients with LVL&#x02009;&#x02265;&#x02009;8.5 (high) (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.0001). Crude analysis showed a non-statistically significant difference in CFR between Lakka-ETC and Goderich-ETC-ICU patient admissions (57.7 vs 50.0%; <italic>p&#x02009;</italic>=&#x02009;0.19) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). Multivariable logistic regression analysis showed that age and viral load were independently associated with an increase in EVD mortality. The best model (according to the lowest AIC) for predicting the probability of death included age, LVL, ETC, and the interaction between LVL and ETC. As known, an interaction involving a continuous variable (like LVL) is difficult to represent. Hence, in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> we plotted, as a function of LVL, both the OR for mortality of Lakka vs Goderich (left panel) and the probability of death at each ETC (right panel). In the left panel, the 95% confidence band of the OR (light grey) never exceeds one, while the 80% confidence band (dark grey) exceeds one for medium&#x02013;high viral loads (LVL between 7.5 and 8.5).<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Case fatality rate by main patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Survivors</th><th align="left">Non-survivors</th><th align="left">Case fatality rate (%)</th><th align="left"><italic>p</italic> value<sup>a</sup></th></tr></thead><tbody><tr><td align="left">All patients, <italic>N</italic></td><td align="left">105</td><td align="left">124</td><td align="left">54.1</td><td align="left"/></tr><tr><td align="left">ETC</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Lakka</td><td align="left">52</td><td align="left">71</td><td align="left">57.7</td><td align="left">0.19</td></tr><tr><td align="left">&#x000a0;Goderich</td><td align="left">53</td><td align="left">53</td><td align="left">50.0</td><td align="left"/></tr><tr><td align="left">Sex, <italic>N</italic> (%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Women</td><td align="left">56</td><td align="left">58</td><td align="left">50.9</td><td align="left">0.32</td></tr><tr><td align="left">&#x000a0;Men</td><td align="left">49</td><td align="left">66</td><td align="left">57.4</td><td align="left"/></tr><tr><td align="left">Age (years), mean, median (IQR)</td><td align="left">29.7/27.0/(20.0&#x02013;38.0)</td><td align="left">29.9/27.5/(20.0&#x02013;37.0)</td><td align="left"/><td align="left">0.73</td></tr><tr><td align="left">&#x000a0;0&#x02013;10</td><td align="left">8</td><td align="left">14</td><td align="left">63.6</td><td align="left">0.74</td></tr><tr><td align="left">&#x000a0;11&#x02013;18</td><td align="left">12</td><td align="left">16</td><td align="left">57.1</td><td align="left"/></tr><tr><td align="left">&#x000a0;19&#x02013;45</td><td align="left">70</td><td align="left">75</td><td align="left">51.7</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02265;&#x02009;46</td><td align="left">15</td><td align="left">17</td><td align="left">53.1</td><td align="left"/></tr><tr><td align="left">Missing</td><td align="left">&#x02013;</td><td align="left">2</td><td align="left">&#x02013;</td><td align="left"/></tr><tr><td align="left">LVL at admission, mean, median (IQR)</td><td align="left">7.1/7.1/(6.4&#x02013;7.9)</td><td align="left">8.1/8.2/(7.7&#x02013;8.8)</td><td align="left"/><td align="left">&#x0003c; 0.0001</td></tr><tr><td align="left">&#x000a0;&#x0003c;&#x02009;7.5</td><td align="left">58</td><td align="left">26</td><td align="left">31.0</td><td align="left">&#x0003c; 0.0001</td></tr><tr><td align="left">&#x000a0;7.5&#x02013;8.4</td><td align="left">32</td><td align="left">46</td><td align="left">59.0</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02265;&#x02009;8.5</td><td align="left">5</td><td align="left">42</td><td align="left">89.4</td><td align="left"/></tr><tr><td align="left">&#x000a0;Missing</td><td align="left">10</td><td align="left">10</td><td align="left">&#x02013;</td><td align="left"/></tr><tr><td align="left">Time between symptom onset and hospital admission (days), mean, median (IQR)</td><td align="left">5.1, 5.0 (3.0&#x02013;6.0)</td><td align="left">4.8, 4.0 (3.0&#x02013;7.0)</td><td align="left">4.8, 5.0 (3.0&#x02013;6.0)</td><td align="left">0.39</td></tr><tr><td align="left">&#x000a0;0&#x02013;2</td><td align="left">17</td><td align="left">26</td><td align="left">60.5</td><td align="left">0.42</td></tr><tr><td align="left">&#x000a0;3&#x02013;5</td><td align="left">50</td><td align="left">51</td><td align="left">50.5</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x0003e;&#x02009;5</td><td align="left">33</td><td align="left">43</td><td align="left">56.6</td><td align="left"/></tr><tr><td align="left">&#x000a0;Missing</td><td align="left">5</td><td align="left">4</td><td align="left">&#x02013;</td><td align="left"/></tr></tbody></table><table-wrap-foot><p><italic>LVL</italic>, base-10 logarithm of the viral load, measured in copies per millilitre</p><p><italic>IQR</italic> Interquartile range</p><p><sup>a</sup><italic>&#x003c7;</italic><sup>2</sup> test or Fisher&#x02019;s exact test, or Wilcoxon&#x02019;s Rank-Sum Test for continuous variables</p></table-wrap-foot></table-wrap>
<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Left panel: 95% (light gray) and 80% (dark gray) confidence bands of the OR of Lakka ETC vs Goderich ETC by LVL at admission. Right panel: confidence bands of probability of death by LVL at admission, stratified by ETC: The two 80% confidence bands of the probability of death (dark grey for ETC Lakka, dark blue for ETC-ICU Goderich) do not overlap at LVL values between 7.4 and 8.5, whereas the two 95% confidence bands (light grey, light blue) are not separate. The plot shows that mortality at Lakka steadily increased with the rise in viral load, even for low-medium LVL levels. Conversely, in the medium viral load range, i.e. for LVL up to around 8.3, mortality at Goderich increased less substantially with the increase in LVL. Mortality at the two ETCs was similar at higher viral loads</p></caption><graphic xlink:href="134_2018_5308_Fig1_HTML" id="MO1"/></fig></p><p id="Par33">Notably, as the confidence level varies, the band begins to exceed zero at a confidence level of 94.5%, corresponding to <italic>p</italic>&#x02009;=&#x02009;0.055. This means that patients with a medium&#x02013;high level of viremia at admission, had a statistically significant survival benefit (with 80% confidence level) if admitted to the treatment facility in Goderich with ICU competences and equipment.</p><p id="Par34">Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> shows the importance of the viral load at admission for the outcome of the overall population as Kaplan&#x02013;Meier survival-curve for patients with low, intermediate and high viral loads at admission (panel a). The same analysis split in patient population of Lakka (panel b) and Goderich (panel c) shows how the intermediate line, corresponding to patients with LVL 7.5&#x02013;8.5, is different in the two settings.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Kaplan&#x02013;Meier survival-curve for patients with low, intermediate and high viral loads at admission (<bold>a</bold>) and for Lakka (<bold>b</bold>) and Goderich (<bold>c</bold>), separately</p></caption><graphic xlink:href="134_2018_5308_Fig2_HTML" id="MO2"/></fig>
</p></sec></sec><sec id="Sec14"><title>Discussion</title><p id="Par35">Building an ICU in Sierra Leone dedicated to patients with EVD was founded on the hypothesis that intensive supportive care could improve the prognosis of EVD, and ethically supported by the conviction of the right of everybody to receive the best possible treatment. Based on this framework, the EMERGENCY NGO sought to optimise supportive care in a country where very few hospitals even had an ICU prior to the start of the epidemic.</p><p id="Par36">After the tend-based ETC in Lakka, the Goderich ETC-ICU has been active since December 2014. It was built by the British government and run by EMERGENCY (Supplementary material, S2). The organisation recruited intensivists, infectious disease specialists, and expert nurses from various nations (Supplementary material, S1), coordinating their expertise with the experience of its own staff, specialised in intensive care medicine. Despite a long track record in hospital management in very difficult, dangerous areas and conditions, setting up a multinational ICU compliant with rigorous biosafety requirements and subject to obvious communication barriers among team members and with patients, proved to be a very challenging experience, highlighting the importance of organization, communication and cross-disciplinary and cross-cultural training.</p><p id="Par37">We found that the setup of an ETC-ICU was feasible in a very short time and at relatively limited costs. Intensive supportive treatment shows shorter time to discharge in survivors (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>) and survival advantage in patients with intermediate-severe infection (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Different factors, like delay in admission, organ failure, comorbidities, complications, factors not changed by the availability of intensive care, contribute to the mortality in patients with &#x0201c;low&#x0201d; Ebola viral load (LVL&#x02009;&#x0003c;&#x02009;7.5). Patients with very high viral load (LVL&#x02009;&#x0003e;&#x02009;8.5) may have a very limited benefit from intensive care support without effective antiviral treatment, because of the rapid progression of EVD to fatal multiple organ failure [<xref ref-type="bibr" rid="CR28">28</xref>]. Only exceptionally it was possible to buy enough time for the immune system to clear the virus and reverse organ failure. Only 10% of the patients who needed mechanical ventilation, continuous renal replacement therapy and vasopressors recovered. In the supplementary material S6 we report two case histories, demonstrating how rapid both, worsening and improving, may occur according the clearance/persistence of the viral load.</p><p id="Par38">Despite supportive treatment very close to the new guidelines [<xref ref-type="bibr" rid="CR29">29</xref>] plus IC support, mortality at the ICU-ETC was 50% overall and still 30% in patients with LVL&#x02009;&#x0003c;&#x02009;7.5 (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Our fatality rate is therefore much higher than the rate of 18.5% reported for patients with EVD treated outside of West Africa [<xref ref-type="bibr" rid="CR30">30</xref>]. While it is not possible to make a direct comparison between those two groups of patients and their treatment, there remains undoubtedly an important gap which needs to be investigated. Relevant differences between the two patient populations and the treatments are: 81% of patients treated outside West Africa were Western healthcare workers (vs 1% in our population) with shorter time from symptom onset to diagnosis (3 vs 4&#x000a0;days), lower viral load at admission (mean values of LVL of 7.3 vs 7.8&#x000a0;copies/ml), and earlier treatment onset (4 vs 4.9&#x000a0;days). Moreover, 85% of patients treated in North America and Europe received at least one antiviral drug, and 70% received two or more such treatments. Although the various clinical trials have not demonstrated the efficacy of the investigational treatments, some have exhibited promising findings that could not be adequately investigated [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p></sec><sec id="Sec15"><title>Limitations of the study</title><p id="Par39">Evaluating the efficacy of an intensive care approach, with a limited number of patients, in the framework of a humanitarian intervention during a major epidemic, in one of the world&#x02019;s most recourse-limited regions, is clearly fraught with limitations. Outcome predictors other than age and viral load as pre-existing chronical illness and severity of organ dysfunction could not be included because of lack of complete information.</p><p id="Par40">It is important to recognize that the cause of death, particularly when occurring 10&#x02013;15&#x000a0;days after admission, may not be related solely to EVD but may also be associated with cardiovascular complications or bacterial superinfections. Finally, there is no way of assessing how far a learning curve in the treatment of EVD patients may have influenced outcomes, irrespective of the therapeutic setting. An important mortality reduction is reported in an earlier experience [<xref ref-type="bibr" rid="CR31">31</xref>] but the lack of risk adjustment in the comparison limits the strength of this observation.</p></sec><sec id="Sec16"><title>Conclusions</title><p id="Par41">Provision of intensive care to patients within an EVD epidemic is feasible also in resource-limited settings and may be associated with improved survival and less time in hospital but the outcome with supportive care alone, without effective antiviral treatment, remains unsatisfactory.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec17"><p>Below is the link to the electronic supplementary material.
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="134_2018_5308_MOESM1_ESM.docx"><caption><p>Supplementary material 1 (DOCX 289&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><ack><p>Goderich ETC was built by the Royal Engineers as a proxy for the Department for International Development, UK Government (DFID), in cooperation with EMERGENCY&#x02019;s Technical Division. The ETC&#x02019;s operations were cofounded by DFID and private donations to EMERGENCY. The virology laboratory was upgraded with the support of a grant from the Italian Ministry of Foreign Affairs&#x02013;Direzione General per la Cooperazione allo Sviluppo (DGCS). INMI&#x02019;s research activities were performed thanks to grants from the Italian Ministry of Health (Ricerca Corrente IRCCS and Ricerca Finalizzata). Deployment of laboratory personnel was made possible by a grant from the Italian Ministry of Foreign Affairs&#x02013;DGCS. We thank the EMLab European consortium (IFS/2011/272&#x02013;372; <ext-link ext-link-type="uri" xlink:href="http://www.emlab.eu">http://www.emlab.eu</ext-link>), where we developed knowledge and experience allowing us to establish the virology laboratory at Goderich ETC, and the WHO South Africa Ebola laboratory for performing tests in the early phase of the epidemics. SF was supported by Fondazione Cariplo through Grant [2014&#x02013;1962]. The authors thank Joanne Fleming for her help with the English editing of the text and Alessandro Soave for his help with figures editing.</p></ack><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Conflict of interest</title><p>The authors declare that no competing interests exist.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebola Response Team</surname><given-names>WHO</given-names></name><name><surname>Agua-Agum</surname><given-names>J</given-names></name><name><surname>Allegranzi</surname><given-names>B</given-names></name><name><surname>Ariyarajah</surname><given-names>A</given-names></name><name><surname>Aylward</surname><given-names>R</given-names></name><name><surname>Blake</surname><given-names>IM</given-names></name><name><surname>Barboza</surname><given-names>P</given-names></name><etal/></person-group><article-title>After Ebola in West Africa-unpredictable risks, preventable epidemics</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>587</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1056/NEJMsr1513109</pub-id><pub-id pub-id-type="pmid">27509108</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henao-Restrepo</surname><given-names>AM</given-names></name><name><surname>Camacho</surname><given-names>A</given-names></name><name><surname>Longini</surname><given-names>IM</given-names></name><name><surname>Watson</surname><given-names>CH</given-names></name><name><surname>Edmunds</surname><given-names>WJ</given-names></name><name><surname>Egger</surname><given-names>M</given-names></name><etal/></person-group><article-title>Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial</article-title><source>Lancet</source><year>2017</year><volume>389</volume><fpage>505</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)32621-6</pub-id><?supplied-pmid 28017403?><pub-id pub-id-type="pmid">28017403</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>FC</given-names></name><name><surname>Wurie</surname><given-names>AH</given-names></name><name><surname>Hou</surname><given-names>LH</given-names></name><name><surname>Liang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>YH</given-names></name><name><surname>Russell</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial</article-title><source>Lancet</source><year>2017</year><volume>389</volume><fpage>621</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)32617-4</pub-id><?supplied-pmid 28017399?><pub-id pub-id-type="pmid">28017399</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regules</surname><given-names>JA</given-names></name><name><surname>Beigel</surname><given-names>JH</given-names></name><name><surname>Paolino</surname><given-names>KM</given-names></name><name><surname>Voell</surname><given-names>J</given-names></name><name><surname>Castellano</surname><given-names>AR</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>A recombinant vesicular stomatitis virus Ebola vaccine</article-title><source>N Engl J Med</source><year>2017</year><volume>376</volume><fpage>330</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1414216</pub-id><?supplied-pmid 25830322?><pub-id pub-id-type="pmid">25830322</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gsell</surname><given-names>PS</given-names></name><name><surname>Camacho</surname><given-names>A</given-names></name><name><surname>Kucharski</surname><given-names>AJ</given-names></name><name><surname>Watson</surname><given-names>CH</given-names></name><name><surname>Bagayoko</surname><given-names>A</given-names></name><name><surname>Nadlaou</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report</article-title><source>Lancet Infect Dis</source><year>2017</year><?supplied-pmid 29033032?><pub-id pub-id-type="pmid">29033032</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schieffelin</surname><given-names>JS</given-names></name></person-group><article-title>An effective and safe vaccine will not be enough to prepare us for the next Ebola outbreak</article-title><source>Lancet Infect Dis</source><year>2017</year><?supplied-pmid 29033035?><pub-id pub-id-type="pmid">29033035</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baseler</surname><given-names>L</given-names></name><name><surname>Chertow</surname><given-names>DS</given-names></name><name><surname>Johnson</surname><given-names>KM</given-names></name><name><surname>Feldmann</surname><given-names>H</given-names></name><name><surname>Morens</surname><given-names>DM</given-names></name></person-group><article-title>The pathogenesis of Ebola virus disease</article-title><source>Annu Rev Pathol</source><year>2017</year><volume>12</volume><fpage>387</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-052016-100506</pub-id><?supplied-pmid 27959626?><pub-id pub-id-type="pmid">27959626</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>PREVAIL II Writing Group</collab><collab>Multi-National PREVAIL II Study Team</collab><name><surname>Davey</surname><given-names>RT</given-names><suffix>Jr</suffix></name><name><surname>Dodd</surname><given-names>L</given-names></name><name><surname>Proschan</surname><given-names>MA</given-names></name><name><surname>Neaton</surname><given-names>J</given-names></name><name><surname>Neuhaus Nordwall</surname><given-names>J</given-names></name><name><surname>Koopmeiners</surname><given-names>JS</given-names></name><etal/></person-group><article-title>A randomized, controlled trial of ZMapp for Ebola virus infection</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>1448</fpage><lpage>1456</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1604330</pub-id><pub-id pub-id-type="pmid">27732819</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunning</surname><given-names>J</given-names></name><name><surname>Kennedy</surname><given-names>SB</given-names></name><name><surname>Antierens</surname><given-names>A</given-names></name><name><surname>Whitehead</surname><given-names>J</given-names></name><name><surname>Ciglenecki</surname><given-names>I</given-names></name><name><surname>Carson</surname><given-names>G</given-names></name><etal/></person-group><article-title>Experimental treatment of Ebola virus disease with brincidofovir</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><fpage>e0162199</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0162199</pub-id><?supplied-pmid 27611077?><pub-id pub-id-type="pmid">27611077</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunning</surname><given-names>J</given-names></name><name><surname>Sahr</surname><given-names>F</given-names></name><name><surname>Rojek</surname><given-names>A</given-names></name><name><surname>Gannon</surname><given-names>F</given-names></name><name><surname>Carson</surname><given-names>G</given-names></name><name><surname>Idriss</surname><given-names>B</given-names></name><collab>Experimental Treatment of Ebola Virus Disease with TKM-130803</collab><etal/></person-group><article-title>A single-arm Phase 2 clinical trial</article-title><source>PLoS Med</source><year>2016</year><volume>13</volume><issue>4</issue><fpage>e1001997</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1001997</pub-id><?supplied-pmid 27093560?><pub-id pub-id-type="pmid">27093560</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sissoko</surname><given-names>D</given-names></name><name><surname>Laouenan</surname><given-names>C</given-names></name><name><surname>Folkesson</surname><given-names>E</given-names></name><name><surname>M&#x02019;Lebing</surname><given-names>AB</given-names></name><name><surname>Beavogui</surname><given-names>AH</given-names></name><name><surname>Baize</surname><given-names>S</given-names></name><etal/></person-group><article-title>Experimental Treatment with Favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea</article-title><source>PLoS Med</source><year>2016</year><volume>13</volume><fpage>e1001967</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1001967</pub-id><?supplied-pmid 26930627?><pub-id pub-id-type="pmid">26930627</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gignoux</surname><given-names>E</given-names></name><name><surname>Azman</surname><given-names>AS</given-names></name><name><surname>de Smet</surname><given-names>M</given-names></name><name><surname>Azuma</surname><given-names>P</given-names></name><name><surname>Massaquoi</surname><given-names>M</given-names></name><name><surname>Job</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effect of artesunate&#x02013;amodiaquine on mortality related to Ebola virus disease</article-title><source>New Engl J Med</source><year>2016</year><volume>374</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1504605</pub-id><?supplied-pmid 26735991?><pub-id pub-id-type="pmid">26735991</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Griensven</surname><given-names>J</given-names></name><name><surname>Edwards</surname><given-names>T</given-names></name><name><surname>de Lamballerie</surname><given-names>X</given-names></name><name><surname>Semple</surname><given-names>MG</given-names></name><name><surname>Gallian</surname><given-names>P</given-names></name><name><surname>Baize</surname><given-names>S</given-names></name><etal/></person-group><article-title>Evaluation of convalescent plasma for Ebola virus disease in Guinea</article-title><source>N Engl J Med</source><year>2016</year><volume>374</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1511812</pub-id><?supplied-pmid 26735992?><pub-id pub-id-type="pmid">26735992</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Medicines Sans Fronti&#x000e8;res, Sterk E, Borchert M, Coeur C, Dorion C, Fabiansen C, Flevaud L et al (2008) Filovirus haemorrhagic fever guideline 2008, chapter 5: patient care. <ext-link ext-link-type="uri" xlink:href="https://www.medbox.org/ebola-guidelines/listing">https://www.medbox.org/ebola-guidelines/listing</ext-link>. Accessed July 2017</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>RA</given-names></name><name><surname>Fletcher</surname><given-names>T</given-names></name><name><surname>Fischer</surname><given-names>WA</given-names></name><name><surname>Lamontagne</surname><given-names>F</given-names></name><name><surname>Jacob</surname><given-names>S</given-names></name><name><surname>Brett-Major</surname><given-names>D</given-names></name><etal/></person-group><article-title>Caring for critically ill patients with Ebola virus disease. Perspectives from West Africa</article-title><source>Am J Respir Crit Care Med</source><year>2014</year><volume>19</volume><fpage>733</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1164/rccm.201408-1514CP</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perner</surname><given-names>A</given-names></name><name><surname>Fowler</surname><given-names>RA</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Roberts</surname><given-names>I</given-names></name></person-group><article-title>Ebola care and research protocols</article-title><source>Intensive Care Med</source><year>2015</year><volume>41</volume><fpage>111</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1007/s00134-014-3568-1</pub-id><?supplied-pmid 25427868?><pub-id pub-id-type="pmid">25427868</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faye</surname><given-names>O</given-names></name><name><surname>Andronico</surname><given-names>A</given-names></name><name><surname>Faye</surname><given-names>O</given-names></name><name><surname>Salje</surname><given-names>H</given-names></name><name><surname>Bo&#x000eb;lle</surname><given-names>PY</given-names></name><name><surname>Magassouba</surname><given-names>N</given-names></name><etal/></person-group><article-title>Use of viremia to evaluate the baseline case fatality ratio of Ebola virus disease and inform treatment studies: a retrospective cohort study</article-title><source>PLoS Med</source><year>2015</year><volume>12</volume><fpage>e1001908</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1001908</pub-id><?supplied-pmid 26625118?><pub-id pub-id-type="pmid">26625118</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schieffelin</surname><given-names>JS</given-names></name><name><surname>Shaffer</surname><given-names>JG</given-names></name><name><surname>Goba</surname><given-names>A</given-names></name><name><surname>Gbakie</surname><given-names>M</given-names></name><name><surname>Gire</surname><given-names>SK</given-names></name><name><surname>Colubri</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clinical illness and outcomes in patients with Ebola in Sierra Leone</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><fpage>2092</fpage><lpage>2100</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1411680</pub-id><?supplied-pmid 25353969?><pub-id pub-id-type="pmid">25353969</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanini</surname><given-names>S</given-names></name><name><surname>Portella</surname><given-names>G</given-names></name><name><surname>Vairo</surname><given-names>F</given-names></name><name><surname>Kobinger</surname><given-names>GP</given-names></name><name><surname>Pesenti</surname><given-names>A</given-names></name><name><surname>Langer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Blood kinetics of Ebola virus in survivors and non-survivors</article-title><source>J Clin Invest</source><year>2015</year><volume>125</volume><fpage>4692</fpage><lpage>4698</lpage><pub-id pub-id-type="doi">10.1172/JCI83111</pub-id><?supplied-pmid 26551684?><pub-id pub-id-type="pmid">26551684</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de La Vega</surname><given-names>MA</given-names></name><name><surname>Caleo</surname><given-names>G</given-names></name><name><surname>Audet</surname><given-names>J</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Kozak</surname><given-names>RA</given-names></name><name><surname>Brooks</surname><given-names>JI</given-names></name><etal/></person-group><article-title>Ebola viral load at diagnosis associates with patient outcome and outbreak evolution</article-title><source>J Clin Invest</source><year>2015</year><volume>125</volume><fpage>4421</fpage><lpage>4428</lpage><pub-id pub-id-type="doi">10.1172/JCI83162</pub-id><pub-id pub-id-type="pmid">26551677</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzpatrick</surname><given-names>G</given-names></name><name><surname>Vogt</surname><given-names>F</given-names></name><name><surname>Moi Gbabai</surname><given-names>OB</given-names></name><name><surname>Decroo</surname><given-names>T</given-names></name><name><surname>Keane</surname><given-names>M</given-names></name><name><surname>De Clerck</surname><given-names>H</given-names></name><etal/></person-group><article-title>The contribution of Ebola viral load at admission and other patient characteristics to mortality in a M&#x000e9;decins Sans Fronti&#x000e8;res Ebola Case Management Centre, Kailahun, Sierra Leone, June&#x02013;October 2014</article-title><source>J Infect Dis</source><year>2015</year><volume>212</volume><fpage>1752</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv304</pub-id><?supplied-pmid 26002981?><pub-id pub-id-type="pmid">26002981</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>L</given-names></name><name><surname>Gupta-Wright</surname><given-names>A</given-names></name><name><surname>Simms</surname><given-names>V</given-names></name><name><surname>Tamba</surname><given-names>F</given-names></name><name><surname>Knott</surname><given-names>V</given-names></name><name><surname>Tamba</surname><given-names>K</given-names></name><etal/></person-group><article-title>Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study</article-title><source>Lancet Infect Dis</source><year>2015</year><volume>15</volume><fpage>1292</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)00144-9</pub-id><?supplied-pmid 26271406?><pub-id pub-id-type="pmid">26271406</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crowe</surname><given-names>SJ</given-names></name><name><surname>Maenner</surname><given-names>MJ</given-names></name><name><surname>Kuah</surname><given-names>S</given-names></name><name><surname>Erickson</surname><given-names>BR</given-names></name><name><surname>Coffee</surname><given-names>M</given-names></name><name><surname>Knust</surname><given-names>B</given-names></name><etal/></person-group><article-title>Prognostic indicators for Ebola patient survival</article-title><source>Emerg Infect Dis</source><year>2016</year><volume>22</volume><fpage>217</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.3201/eid2202.151250</pub-id><?supplied-pmid 26812579?><pub-id pub-id-type="pmid">26812579</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salata</surname><given-names>C</given-names></name><name><surname>Baritussio</surname><given-names>A</given-names></name><name><surname>Munegato</surname><given-names>D</given-names></name><name><surname>Calistri</surname><given-names>A</given-names></name><name><surname>Ha</surname><given-names>HR</given-names></name><name><surname>Bigler</surname><given-names>L</given-names></name><etal/></person-group><article-title>Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process</article-title><source>Pathog Dis</source><year>2015</year><?supplied-pmid 25933611?><pub-id pub-id-type="pmid">25933611</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenfeld</surname><given-names>DA</given-names></name><name><surname>Bernard</surname><given-names>GR</given-names></name></person-group><article-title>Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome</article-title><source>Crit Care Med</source><year>2002</year><volume>30</volume><fpage>1772</fpage><lpage>1777</lpage><pub-id pub-id-type="doi">10.1097/00003246-200208000-00016</pub-id><?supplied-pmid 12163791?><pub-id pub-id-type="pmid">12163791</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akaike</surname><given-names>H</given-names></name></person-group><article-title>A new look at the statistical model identification</article-title><source>IRRR Trans Autom Control</source><year>1974</year><volume>19</volume><fpage>716</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1109/TAC.1974.1100705</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Payton</surname><given-names>ME</given-names></name><name><surname>Greenstone</surname><given-names>MH</given-names></name><name><surname>Schenker</surname><given-names>N</given-names></name></person-group><article-title>Overlapping confidence intervals or standard error intervals: what do they mean in terms of statistical significance?</article-title><source>J Insect Sci</source><year>2003</year><volume>34</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1673/031.003.3401</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanini</surname><given-names>S</given-names></name><name><surname>Portella</surname><given-names>G</given-names></name><name><surname>Vairo</surname><given-names>F</given-names></name><name><surname>Kobinger</surname><given-names>GP</given-names></name><name><surname>Pesenti</surname><given-names>A</given-names></name><name><surname>Langer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Relationship between viremia and specific organ damage in Ebola patients: a cohort study</article-title><source>Clin Infect Dis</source><year>2017</year><volume>66</volume><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1093/cid/cix704</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamontagne</surname><given-names>F</given-names></name><name><surname>Fowler</surname><given-names>RA</given-names></name><name><surname>Adhikari</surname><given-names>NK</given-names></name><name><surname>Murthy</surname><given-names>S</given-names></name><name><surname>Brett-Major</surname><given-names>DM</given-names></name><name><surname>Jacobs</surname><given-names>M</given-names></name><etal/></person-group><article-title>Evidence-based guidelines for supportive care of patients with Ebola virus disease</article-title><source>Lancet</source><year>2018</year><volume>39</volume><fpage>700</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31795-6</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uyeki</surname><given-names>TM</given-names></name><name><surname>Mehta</surname><given-names>AK</given-names></name><name><surname>Davey</surname><given-names>RT</given-names><suffix>Jr</suffix></name><name><surname>Liddell</surname><given-names>AM</given-names></name><name><surname>Wolf</surname><given-names>T</given-names></name><name><surname>Vetter</surname><given-names>P</given-names></name><etal/></person-group><article-title>Clinical management of Ebola virus disease in the United States and Europe</article-title><source>N Engl J Med</source><year>2016</year><volume>374</volume><fpage>636</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1504874</pub-id><?supplied-pmid 26886522?><pub-id pub-id-type="pmid">26886522</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansumana</surname><given-names>R</given-names></name><name><surname>Jacobsen</surname><given-names>KH</given-names></name><name><surname>Sahr</surname><given-names>F</given-names></name><name><surname>Idris</surname><given-names>M</given-names></name><name><surname>Bangura</surname><given-names>H</given-names></name><name><surname>Boie-Jalloh</surname><given-names>M</given-names></name><name><surname>Lamin</surname><given-names>JM</given-names></name><name><surname>Sesay</surname><given-names>S</given-names></name></person-group><article-title>Ebola in Freetown area, Sierra Leone&#x02014;a case study of 581 patients</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><fpage>587</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1413685</pub-id><?supplied-pmid 25539447?><pub-id pub-id-type="pmid">25539447</pub-id></element-citation></ref></ref-list></back></article>